% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Banales:306915,
      author       = {J. M. Banales and P. M. Rodrigues and S. Affò and J. B.
                      Andersen and P. Aspichueta and L. Boulter and J. Bridgewater
                      and D. F. Calvisi and A. Cardenas and V. Cardinale and G.
                      Carpino and C. Coulouarn and C. Dopazo and J. Edeline and L.
                      Fabris and T. Folseraas and A. Forner and B. Goeppert and M.
                      Heikenwalder$^*$ and T. J. Kendall and S. A. Khan and H.-J.
                      Klümpen and B. G. Koerkamp and A. Lamarca and S. Lindsey
                      and A. Lleo and T. Luedde and R. I. R. Macias and H.
                      Morement and J.-C. Nault and P. Olaizola and M. J.
                      Perugorria and C. Raggi and L. Rimassa and A. Saborowski and
                      J. W. Valle and M. Vithayathil and A. Vogel and C. Braconi},
      collaboration = {I. C. C. Consortium},
      othercontributors = {A. Sanchez and A. La Casta and A. J. Montano-Loza and A.
                          Elvevi and A. Parisi and A. Link and A. Landa-Magdalena and
                          A. Munoz and A. Turpin and A. Ustav and A. Jusakul and A.
                          Valsan and B. Dwyer and B. S. Ungureanu and B. Sangro and C.
                          Schramm and C. Neuzillet and C. Fondevila and D. J. Pinato
                          and D. Malka and D. Balderramo and E. Gutierrez and E.
                          Lozano and E. Boleslawski and E. C. Estupinan and E.
                          Sparrelid and E. Gaudio and F. H. De La Tijera and F. Rocha
                          and F. Troisfontaine and F. Ratti and F. Lammert and G.
                          Vidili and G. Sapisochin and G. B. Lesinski and G. Gores and
                          H. Jansson and H. Malik and J. P. Jonas and J. D. Ferrer and
                          J. Vaquero and J. U. Marquardt and J. E. Santo and J. Adeva
                          and J. Erdmann and J. J. G. Marin and J. C. Roa and J.
                          Busquets and J. Kupcinskas and K. Zieniewicz and L. Heij and
                          L. Goff and L. Izquierdo-Sanchez and L. G. Da Fonseca and L.
                          Maroni and L. Bujanda and M. G. McNamara and M. Carbone and
                          M. Marzioni and M. Rengo and M. M. Deutsch and M. Ponz and
                          M. Strazzabosco and M. Peck-Radosavljevic and M. Cadamuro
                          and M. Salati and M. Colombo and M. Mandea and M. A. Avila
                          and M. Evert and M. Komuta and M. Borad and M. Bouattour and
                          M. El-Kassas and M. I. Meneses-Medina and M. Niger and M.
                          Verstegen and N. Bardeesy and N. Azad and O. Detry and O.
                          Scatton and P. M. Padilla-Machaca and P. Acedo and P. B.
                          Olthof and P. Milkiewicz and R. Guest and R. Shroff and R.
                          Montal and R. K. Kelley and R. Xue and S. Gradilone and S.
                          K. Maithel and S. Vicent and S. Jirawatnotai and S. Caruso
                          and S. Roessler and S. L. Chan and S. P. Pereira and T.
                          Macarulla and T. Gruenberger and T. V. Tian and T. F. Greten
                          and T. Mocan and T. Patel and U. Mahmood and U. Cillo and V.
                          Megdanova and V. Lopez-Lopez},
      title        = {{C}holangiocarcinoma 2026: status quo, unmet needs and
                      priorities.},
      journal      = {Nature reviews / Gastroenterology $\&$ hepatology},
      volume       = {23},
      number       = {1},
      issn         = {1759-5045},
      address      = {Basingstoke},
      publisher    = {Nature Publishing Group},
      reportid     = {DKFZ-2025-02889},
      pages        = {65-96},
      year         = {2026},
      note         = {2026 Jan;23(1):65-96. doi: 10.1038/s41575-025-01153-w. Epub
                      2025 Dec 10},
      abstract     = {Cholangiocarcinoma (CCA) is a cancer that originates within
                      the bile ducts. Traditionally considered to be a rare
                      neoplasm, increased awareness of CCA alongside advancements
                      in diagnosis and the rising prevalence of certain risk
                      factors have contributed to a global increase in incidence
                      and mortality. CCAs are highly heterogeneous from the
                      clinical, histomorphological and molecular perspectives but
                      commonly share a poor prognosis. These tumours usually
                      develop and progress silently; by the time they are
                      detected, it is often too late for curative surgical
                      intervention. In such cases, current therapeutic approaches
                      offer modest survival improvements and are generally
                      considered palliative. Although well-known risk factors
                      predispose individuals to developing CCA, the majority of
                      cases are considered sporadic, occurring without any
                      identifiable underlying condition. Over the past decade,
                      substantial collaborative efforts have been made to improve
                      our understanding of the aetiopathogenesis of these tumours,
                      aiming to identify novel biomarkers and therapeutic targets
                      to develop more effective treatments. The ultimate goal is
                      to improve patient outcomes and overall well-being. However,
                      there are significant gaps in our understanding of the
                      molecular mechanisms that drive cholangiocarcinogenesis. In
                      this international Consensus Statement, which is endorsed by
                      the European Network for the Study of Cholangiocarcinoma, we
                      provide a critical overview of the latest advancements in
                      the field of CCA. We highlight the key aspects of CCA
                      aetiopathogenesis and clinical management and provide
                      insights into promising new treatments. Finally, we provide
                      a set of consensus recommendations and future research
                      priorities for CCA based on a Delphi panel questionnaire
                      involving international experts.},
      subtyp        = {Review Article},
      cin          = {D440},
      ddc          = {610},
      cid          = {I:(DE-He78)D440-20160331},
      pnm          = {314 - Immunologie und Krebs (POF4-314)},
      pid          = {G:(DE-HGF)POF4-314},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:41372578},
      doi          = {10.1038/s41575-025-01153-w},
      url          = {https://inrepo02.dkfz.de/record/306915},
}